Vol. 6 No. 3 (2026)
Reimbursement Reviews

Olaparib

decorative image of the issue cover

Published March 25, 2026

Key Messages

  • Reimbursement reviews of drugs later in the life cycle include a comprehensive assessment of clinical value, unmet clinical need, distinct social and ethical considerations, economic considerations, and impacts on the health systems.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial drug plans and cancer agencies.
  • This review assesses olaparib 100 mg and 150 mg oral tablets.
  • Indication under consideration for reimbursement: For the maintenance treatment of adult patients with deleterious or suspected deleterious gBRCA-mutated locally advanced unresectable or metastatic adenocarcinoma of the pancreas whose disease has not progressed on prior systemic therapy.